New allelic arrangement CYP2D6*36x2 found in a Japanese poor metabolizer of debrisoquine

被引：19
|
作者：
Chida, M
Ariyoshi, N
Yokoi, T
Nemoto, N
Inaba, M
Kinoshita, M
Kamataki, T
机构：
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Div Pharmacobiodynam, Sapporo, Hokkaido, Japan
[2] Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Toxicol, Toyama, Japan
[3] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan
[4] Otsuka Pharmaceut Co Ltd, Tokushima 77101, Japan
来源：
PHARMACOGENETICS | 2002年 / 12卷 / 08期
关键词：
CYP2D6*10; gene duplication; genotype;
D O I：
10.1097/00008571-200211000-00011
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
[No abstract available]
引用
收藏
页码：659 / 662
页数：4
相关论文
共 50 条
  • [21] Clinical Significance of a CYP2D6 Poor Metabolizer-A Patient With Schizophrenia on Risperidone Treatment
    Bozina, Nada
    Jovanovic, Nikolina
    Lovric, Mila
    Medved, Vesna
    THERAPEUTIC DRUG MONITORING, 2008, 30 (06) : 748 - 751
  • [22] Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype
    Ganesh, Soraya, V
    Beunk, Lianne
    Nikolik, Bojan
    van der Weide, Jan
    Bet, Pierre M.
    THERAPEUTIC DRUG MONITORING, 2021, 43 (05) : 672 - 680
  • [23] THE DEMETHYLENATION OF METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) BY DEBRISOQUINE HYDROXYLASE (CYP2D6)
    TUCKER, GT
    LENNARD, MS
    ELLIS, SW
    WOODS, HF
    CHO, AK
    LIN, LY
    HIRATSUKA, A
    SCHMITZ, DA
    CHU, TYY
    BIOCHEMICAL PHARMACOLOGY, 1994, 47 (07) : 1151 - 1156
  • [24] DEBRISOQUINE HYDROXYLATION (CYP2D6) PHENOTYPE ASSIGNMENT BY GENOTYPING
    DALY, AK
    ARMSTRONG, M
    MONKMAN, SC
    IDLE, ME
    IDLE, JR
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (04) : 110 - 110
  • [25] CYP2D6 (debrisoquine metabolism) and lung cancer histology
    Marcus, P
    Rothman, N
    Caporaso, N
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2000, 151 (11) : S25 - S25
  • [26] ENDOGENOUS CODEINE AND MORPHINE IN POOR AND EXTENSIVE METABOLIZERS OF THE CYP2D6 (DEBRISOQUINE/SPARTEINE) POLYMORPHISM
    MIKUS, G
    BOCHNER, F
    EICHELBAUM, M
    HORAK, P
    SOMOGYI, AA
    SPECTOR, S
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1994, 268 (02): : 546 - 551
  • [27] In vitro characterization of new CYP2D6 allelic variants.
    Marcucci, KA
    Walker, T
    Gotschall, RR
    Pearce, RE
    Hurwitz, I
    Leeder, JS
    Gaedigk, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P94 - P94
  • [28] POLYMORPHIC CYP2D6 GENOTYPES ASSOCIATED WITH DEFICIENT METABOLISM OF DEBRISOQUINE SPARTEINE IN JAPANESE POPULATION
    KONDO, I
    OKANO, K
    YONAHA, M
    GONZALEZ, FJ
    KANAZAWA, I
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (04) : 112 - 112
  • [29] Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics
    Ohmori, O
    Suzuki, T
    Kojima, H
    Shinkai, T
    Terao, T
    Mita, T
    Abe, K
    SCHIZOPHRENIA RESEARCH, 1998, 32 (02) : 107 - 113
  • [30] A NOVEL CYP2D6 ALLELE WITH AN ABOLISHED SPLICE RECOGNITION SITE ASSOCIATED WITH THE POOR METABOLIZER PHENOTYPE
    MAREZ, D
    SABBAGH, N
    LEGRAND, M
    LOGUIDICE, JM
    BOONE, P
    BROLY, F
    PHARMACOGENETICS, 1995, 5 (05): : 305 - 311
12345